Innovation in India has been boosted, especially after the success of 5+ NME launches.

Holistic innovation continues to lag other markets, driven by gaps across all elements of innovation.

Regulatory landscape

While some improvements have been made over the last few years, the overall regulatory framework continues to have several gaps. The challenges are across:

- Complexity in the approval process
- Subjectivity in reviews, driven by lack of adequate guidelines and variability in expert inputs
- Long process due to lack of defined timelines
- Challenges in capacity and capability of the regulatory body
- Absence of accelerated approval pathways
- Gaps in transparency and collaboration with industry

These gaps lead to a long approval timeline in India and significantly impede the pace of innovation in the country.

Funding support

The level of funding for pharma innovation in India continues to be significantly lower than in other markets. It is critical to improve the effectiveness of the existing spend and shift it towards early-stage research.

Reward for innovation

Competitive pricing levels in the Indian market and the lack of any central reimbursement programs that can facilitate uptake, limits the opportunity for innovative products in the country.

Quality of research in academia and industry collaboration

The quality of local research in India also continues to lag global leaders, driven by multiple challenges. Multiple challenges in the performance management approach, supporting infrastructure and structured collaboration with the industry are driving these challenges.

Quality of local talent

India continues to lack the high-quality talent required to drive innovation effectively in the country. The quality of local talent is impacted by curriculum and lack of adequate industry exposure in universities.

Limited at-scale innovation hubs with best-in-class infrastructure